Literature DB >> 30030599

[Nonmuscle invasive bladder cancer : Efficacy of electromotive drug administration].

Arkadiusz Miernik1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30030599     DOI： 10.1007/s00120-018-0737-9

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  8 in total

1.  Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.

Authors:  Savino M Di Stasi; Marco Valenti; Cristian Verri; Emanuele Liberati; Arcangelo Giurioli; Gioia Leprini; Francesco Masedu; Antonio R Ricci; Francesco Micali; Giuseppe Vespasiani
Journal:  Lancet Oncol       Date:  2011-08-08       Impact factor: 41.316

Review 2.  A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.

Authors:  Maurizio Brausi; J Alfred Witjes; Donald Lamm; Raj Persad; Joan Palou; Marc Colombel; Roger Buckley; Mark Soloway; Hideyuki Akaza; Andreas Böhle
Journal:  J Urol       Date:  2011-10-19       Impact factor: 7.450

Review 3.  Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.

Authors:  Pan Feng Shang; Joey Kwong; Zhi Ping Wang; Jinhui Tian; Lei Jiang; Kehu Yang; Zhong Jin Yue; Jun Qiang Tian
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

4.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.

Authors:  Marko Babjuk; Andreas Böhle; Maximilian Burger; Otakar Capoun; Daniel Cohen; Eva M Compérat; Virginia Hernández; Eero Kaasinen; Joan Palou; Morgan Rouprêt; Bas W G van Rhijn; Shahrokh F Shariat; Viktor Soukup; Richard J Sylvester; Richard Zigeuner
Journal:  Eur Urol       Date:  2016-06-17       Impact factor: 20.096

5.  Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.

Authors:  Savino M Di Stasi; Antonella Giannantoni; Arcangelo Giurioli; Marco Valenti; Germano Zampa; Luigi Storti; Francesco Attisani; Andrea De Carolis; Giovanni Capelli; Giuseppe Vespasiani; Robert L Stephen
Journal:  Lancet Oncol       Date:  2006-01       Impact factor: 41.316

6.  Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression.

Authors:  Massimo Maffezzini; Fabio Campodonico; Giorgio Canepa; Egi Edward Manuputty; Stefania Tamagno; Matteo Puntoni
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-01       Impact factor: 3.333

7.  Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.

Authors:  Savino M Di Stasi; Antonella Giannantoni; Robert L Stephen; Giovanni Capelli; Pierluigi Navarra; Renato Massoud; Giuseppe Vespasiani
Journal:  J Urol       Date:  2003-09       Impact factor: 7.450

Review 8.  Intravesical electromotive drug administration for non-muscle invasive bladder cancer.

Authors:  Jae Hung Jung; Ahmet Gudeloglu; Halil Kiziloz; Gretchen M Kuntz; Alea Miller; Badrinath R Konety; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2017-09-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.